| |
| |
|
| Insider
Information: |
Prasad Suyash |
| Relationship: |
CMO and Head of R&D |
| City: |
San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
548,068 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$1,048,216 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
548,068 |
|
|
| Total
Value |
$1,048,216 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Audentes Therapeutics, Inc. |
BOLD |
Senior VP & Chief Med ... |
2019-06-05 |
17,479 |
2017-09-01 |
0 |
Premium* |
|
|
Taysha Gene Therapies, Inc. |
TSHA |
CMO and Head of R&D |
2022-07-06 |
530,589 |
2020-09-23 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| TSHA |
Taysha Gene Therapies, In... |
CMO and Head of R&D |
• – – |
2022-07-06 |
4 |
AS |
$3.79 |
$33,943 |
D/D |
(8,956) |
530,589 |
0 |
- |
|
| TSHA |
Taysha Gene Therapies, In... |
CMO and Head of R&D |
• – – |
2022-07-05 |
4 |
AS |
$3.51 |
$13,707 |
D/D |
(3,905) |
539,545 |
0 |
- |
|
| TSHA |
Taysha Gene Therapies, In... |
CMO and Head of R&D |
• – – |
2022-07-01 |
4 |
AS |
$3.53 |
$84,448 |
D/D |
(23,923) |
543,450 |
0 |
- |
|
| TSHA |
Taysha Gene Therapies, In... |
CMO and Head of R&D |
• – – |
2022-06-30 |
4 |
AS |
$3.72 |
$51,678 |
D/D |
(13,892) |
567,373 |
0 |
- |
|
| TSHA |
Taysha Gene Therapies, In... |
CMO and Head of R&D |
• – – |
2022-06-29 |
4 |
AS |
$3.81 |
$46,954 |
D/D |
(12,324) |
581,265 |
0 |
- |
|
| TSHA |
Taysha Gene Therapies, In... |
CMO and Head of R&D |
• – – |
2021-07-01 |
4 |
AS |
$21.12 |
$416,191 |
D/D |
(19,706) |
593,589 |
0 |
- |
|
| TSHA |
Taysha Gene Therapies, In... |
CMO and Head of R&D |
• – – |
2021-06-30 |
4 |
AS |
$21.42 |
$437,494 |
D/D |
(20,076) |
613,295 |
0 |
- |
|
| TSHA |
Taysha Gene Therapies, In... |
CMO and Head of R&D |
• – – |
2021-06-29 |
4 |
AS |
$23.74 |
$934,251 |
D/D |
(39,218) |
633,371 |
0 |
- |
|
| TSHA |
Taysha Gene Therapies, In... |
CMO and Head of R&D |
• – – |
2020-09-28 |
4 |
A |
$0.00 |
$0 |
D/D |
3,844 |
672,589 |
0 |
- |
|
| TSHA |
Taysha Gene Therapies, In... |
CMO and Head of R&D |
• – – |
2020-09-23 |
4 |
A |
$0.00 |
$0 |
D/D |
668,745 |
668,745 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
Senior VP & Chief Med Officer |
• – – |
2019-06-05 |
4 |
D |
$37.31 |
$28,244 |
D/D |
(757) |
17,479 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
Senior VP & Chief Med Officer |
• – – |
2019-02-25 |
4 |
AS |
$30.06 |
$300,553 |
D/D |
(10,000) |
18,236 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
Senior VP & Chief Med Officer |
• – – |
2019-02-25 |
4 |
OE |
$0.79 |
$7,900 |
D/D |
10,000 |
28,236 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
Senior VP & Chief Med Officer |
• – – |
2019-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
17,500 |
18,236 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
Senior VP & Chief Med Officer |
• – – |
2018-11-15 |
4 |
A |
$19.64 |
$14,451 |
D/D |
736 |
736 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
Senior VP & Chief Med Officer |
• – – |
2018-10-01 |
4 |
AS |
$35.60 |
$368,788 |
D/D |
(10,000) |
0 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
Senior VP & Chief Med Officer |
• – – |
2018-10-01 |
4 |
OE |
$0.79 |
$7,900 |
D/D |
10,000 |
4,699 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
Senior VP & Chief Med Officer |
• – – |
2018-07-02 |
4 |
AS |
$38.02 |
$384,067 |
D/D |
(10,000) |
0 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
Senior VP & Chief Med Officer |
• – – |
2018-07-02 |
4 |
OE |
$0.79 |
$7,900 |
D/D |
10,000 |
5,011 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
Senior VP & Chief Med Officer |
• – – |
2018-03-29 |
4 |
OE |
$0.79 |
$6,162 |
D/D |
7,800 |
7,800 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
Senior VP & Chief Med Officer |
• – – |
2018-03-27 |
4 |
OE |
$0.79 |
$237 |
D/D |
300 |
300 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
Senior VP & Chief Med Officer |
• – – |
2018-03-26 |
4 |
AS |
$30.00 |
$57,000 |
D/D |
(1,900) |
0 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
Senior VP & Chief Med Officer |
• – – |
2018-03-26 |
4 |
OE |
$0.79 |
$1,501 |
D/D |
1,900 |
1,900 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
Senior VP & Chief Med Officer |
• – – |
2017-12-01 |
4 |
AS |
$28.45 |
$228,264 |
D/D |
(8,000) |
0 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
Senior VP & Chief Med Officer |
• – – |
2017-12-01 |
4 |
OE |
$0.79 |
$6,320 |
D/D |
8,000 |
1,230 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
